Drug Approval | December 27, 2021
Covaxin receives approval for Emergency Use in Children 12-18 years
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Subscribe To Our Newsletter & Stay Updated
